Ask Warren

Hyundai Bioscience

048410 · KOSDAQ · ₩048410 · 현대바이오

₩5,820▼ ₩120 (2.02%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +7.98%
Market cap
₩562B
Enterprise value
₩541B
P/E
—
P/B
5.4×
Dividend yield
0.0%
ROE
−27.7%
Net margin
−861.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−72.9% from the high

₩4,565Today: ₩5,720 – ₩6,240₩21,500

Returns

  • 1W−13.0%
  • 1M−15.0%
  • 3M+0.5%
  • 6M−59.9%
  • YTD+17.2%
  • 1Y+8.0%
Volume today
1,313,448
1.5× the 20-day average
Traded today
₩7.8B
Listed shares
96,505,572
EPS (12 months)
−₩296
Earnings yield −5.1%
SellBuy
AI research · Update noteHyundai Bioscience: Model Estimate Rises to ₩374 per Share, Still Far Below Market PriceThe model estimate more than tripled, but the move was not tied to any new filing or reported result in the data, and the trailing numbers remain those of a small, loss-making company.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

47Normal
  • BuzzNormalBuzz 47 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Coverage is mostly positive, reporting the drug's debut and planned trials at a major US conference. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-14.8% over the last month; the price is below its 20-day average.
  • News impactSome6 news items and filings in two weeks; 0 rated high impact, 1 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩194M at the close (3.3% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 25 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 10.8% of trading value and pointed the same way 20 of 25 times.

  • 2× KODEX KOSDAQ150 Leverage ₩158M
  • 2× TIGER KOSDAQ150 Leverage ₩19M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩11M
  • 2× RISE KOSDAQ150 Futures Leverage ₩3.3M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

Hyundai Bioscience stock overview

Hyundai Bioscience (현대바이오, KRX: 048410) is listed on KOSDAQ, in the Chemicals sector. Hyundai Bioscience is a Korean bio-pharmaceutical and cosmeceutical company, spun off from Hyundai Electronics in 2000, that develops new drugs alongside functional cosmetics. Its shares closed at ₩5,820 on Oct 27, 2026, down 2.02% on the day, giving it a market value of ₩562B.

Key facts

Market cap
₩562B
Sector
Chemicals
Latest price change
−2.02%
As of
Oct 27, 2026
Main business
Hyundai Bioscience is a Korean bio-pharmaceutical and cosmeceutical company, spun off from Hyundai Electronics in 2000, that develops new drugs alongside functional cosmetics.

Quick answers about Hyundai Bioscience

What does Hyundai Bioscience do?
Hyundai Bioscience is a Korean bio-pharmaceutical and cosmeceutical company, spun off from Hyundai Electronics in 2000, that develops new drugs alongside functional cosmetics. Its main products are bio cosmetics, anti-hair-loss cosmetics, and hair tonics, sold through online and offline channels in Japan, the United States, China, Europe, Southeast Asia, and Korea, and it operates a production plant in Gimcheon, North Gyeongsang Province.
What is the market cap of Hyundai Bioscience?
The market capitalisation of Hyundai Bioscience was ₩562B at the close on Oct 27, 2026.
Who are the largest shareholders of Hyundai Bioscience?
According to the latest official filings, the largest reported holders are C&Pharm (11.79%, as of Oct 13, 2026); Samsung Asset Management (4.00%, as of May 29, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (3.13%, as of Jul 31, 2026).
When is the next earnings report from Hyundai Bioscience?
Korean companies rarely announce results dates in advance. Based on when Hyundai Bioscience filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Hyundai Bioscience?
Yes. The National Pension Service held 0.37% of Hyundai Bioscience shares as of Dec 31, 2025.

Company profile

Hyundai Bioscience is a Korean bio-pharmaceutical and cosmeceutical company, spun off from Hyundai Electronics in 2000, that develops new drugs alongside functional cosmetics. Its main products are bio cosmetics, anti-hair-loss cosmetics, and hair tonics, sold through online and offline channels in Japan, the United States, China, Europe, Southeast Asia, and Korea, and it operates a production plant in Gimcheon, North Gyeongsang Province.

Written by AI from the company's latest annual report.

Korean name
현대바이오
Sector
Chemicals
Themes
Biotech (new drugs)
CEO
진근우
Founded
May 2000
Listed
Aug 2002
Listed shares
96,505,572
Fiscal year ends
Month 12
Website
www.hyundaibioscience.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Hyundai Bioscience / 현대바이오 / 048410 / KRX:048410

Source: KRX statistical information